Cel
RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.
Dziedzina nauki
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Temat(-y)
Zaproszenie do składania wniosków
FP7-HEALTH-2010-single-stage
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-IP - Large-scale integrating projectKoordynator
13284 Marseille
Francja
Zobacz na mapie
Uczestnicy (23)
23562 Lubeck
Zobacz na mapie
3000 Leuven
Zobacz na mapie
2333 ZA Leiden
Zobacz na mapie
3015 GD Rotterdam
Zobacz na mapie
75724 Paris
Zobacz na mapie
69120 Heidelberg
Zobacz na mapie
Zakończenie uczestnictwa
6525 XZ Nijmegen
Zobacz na mapie
Zakończenie uczestnictwa
01445 RADEBEUL
Zobacz na mapie
OX1 2JD Oxford
Zobacz na mapie
75794 Paris
Zobacz na mapie
28006 Madrid
Zobacz na mapie
CB2 8AL CAMBRIDGE
Zobacz na mapie
Zakończenie uczestnictwa
CH-8005 ZUERICH
Zobacz na mapie
6020 Innsbruck
Zobacz na mapie
20148 HAMBURG
Zobacz na mapie
201203 SHANGHAI
Zobacz na mapie
305606 DAEJEON
Zobacz na mapie
320 Jhongli
Zobacz na mapie
20122 Milano
Zobacz na mapie
Zakończenie uczestnictwa
04109 Leipzig
Zobacz na mapie
3001 Heverlee
Zobacz na mapie
3584 CS Utrecht
Zobacz na mapie
14195 Berlin
Zobacz na mapie